| in accordan | ice with Regulation (EC) I  | No. 1907/2006 and Regulation (EU) No  | . 2020/878   |                                | (Language:El                                       |
|-------------|---|---|--|--------------------------------|--|
| K           | isaval  | DUEPOL ACQUA SUELOS SATINAD<br>Code : 1656  | 0  |                                |  |
| Version:    | 3 Revi  | sion: 11/03/2024  | Previous revision: 23/1  | 2/2022                         | Date of printing: 11/03/202                        |
| mixtures.T  | his product does not me   | on (EC) No. 1907/2006 (REACH), a s<br>et the classification criteria of Regula<br>rements regarding the content of eac  | afety data sheet (SDS) must be provid<br>tion (EC) No. 1272/2008 (CLP).Theref<br>h section are not applicable. | ed for dange<br>ore, this docι | rous substances or<br>iment is outside the scope o |
| SECTION     | 1: IDENTIFICATION OF  | THE SUBSTANCE/MIXTURE AND   | OF THE COMPANY/UNDERTAKING   |                                |  |
|             | PRODUCT IDENTIFIE<br>DUEPOL ACQUA SUEI<br>Code : 1656   |   |  |                                |  |
|             |   | ED USES OF THE SUBSTANCE  | OR MIXTURE AND USES ADVISE   |                                | ۲.   |
|             | Intended uses (main t<br>Liquid paint.<br><u>Sectors of use:</u><br>Consumer uses (SU21)<br>Professional uses (SU2<br><u>Uses advised against</u>   | echnical functions): [] Indus<br>,<br>2),   | rial [X] Professional [X] Consumer   | <u>rs</u>                      | _  |
|             | consistent with the safe  | ty guidelines provided.   | e, according to Annex XVII of Regula   |                                |  |
|             | Not restricted.   |   |  |                                |  |
|             | PINTURAS ISAVAL, S.I<br>c/Velluters, Parcela 2-14<br>Phone number: +34 96   | 4- P.I. Casanova - 46394 Ribarroja d<br>1640001 - Fax: +34 96 1640002 - wv<br><u>e person responsible for the Safet</u>   | el Turia (Valencia) ESPAÑA<br>/w.isaval.es   |                                |  |
|             | EMERGENCY TELEF   |   |  |                                |  |
|             | +34 96 1640001 8:00-1   |   |  |                                |  |
| SECTION     | 2 : HAZARDS IDENTIF   | CATION  |  |                                |  |
| 2.1         | CLASSIFICATION OF   | THE SUBSTANCE OR MIXTUR   | <u>=:</u>  |                                |  |
|             | under ordinary conditior  |   | ording to the Regulation (EC) no. 2020<br>mical, health safety or environmental h                              |                                |  |
|             | This product does not re<br><u>- Hazard statements:</u><br>None.<br><u>- Precautionary statementary</u><br>P102<br>P271<br>P280<br>P273<br><u>- Supplementary state</u>                                       | nents:<br>Keep out of reach of children.<br>Use only outdoors or in a well-ventila<br>Wear protective gloves and eye prot<br>Avoid release to the environment.      |  | lo. 1272/2008                  | 3~2022/692 (CLP).                                  |
|             |   |   | ne, Reaction mass of 5-chloro-2-methy<br>C 220-239-6] (3:1), 1,2-benzisothiazol-                               |                                |  |
|             | OTHER HAZARDS:  |   | паше.  |                                |  |
|             | Hazards which do not re<br>- Other physicochemic<br>No other relevant adver<br>- Other adverse huma<br>No other relevant adver<br>- Other negative envir<br>Does not contain substa<br>Endocrine disrupting p | cal hazards:<br>se effects are known.<br>in health effects:<br>se effects are known.<br>onmental effects:<br>ances that fulfil the PBT/vPvB criteria<br>properties: | ontribute to the overall hazards of the r  |                                |  |
| 1           |   |   |  |                                |  |

| $\square$ | <b>ISAVA</b>  | Code : 1656   |  |  |  |  |  |  |  |
|-----------|---|---|--|--|--|--|--|--|--|
| ersion    |   |   | Previous revision: 23/12/2022  | Date   | of printing: 11/03/20  |  |  |  |  |
| CTION     |   | ORMATION ON INGREDIENTS   |  |  |  |  |  |  |  |
| .1        | SUBSTANCES:   |   |  |  |  |  |  |  |  |
|           | Not applicable (mixture   | ).  |  |  |  |  |  |  |  |
| .2        | MIXTURES:   |   |  |  |  |  |  |  |  |
|           | This product is a mixtur<br>Chemical description  |   |  |  |  |  |  |  |  |
|           |   | d acrylic resin in aqueous media.   |  |  |  |  |  |  |  |
|           | HAZARDOUS INGRE   |   |  |  |  |  |  |  |  |
|           |   | in a percentage higher than the exemption limit:  |  |  |  |  |  |  |  |
| ľ         |   | 1,2-benzisothiazol-3(2H)-one  |  | CLP00  | Skin Sens. 1, H31  |  |  |  |  |
|           |   | CAS: 2634-33-5, EC: 220-120-9   |  |  | C ≥0,05  |  |  |  |  |
|           |   | CLP: Danger: Acute Tox. (oral) 4:H302 (ATE=567 mg/kg)<br>Eye Dam. 1:H318   Skin Sens. 1:H317   Aquatic Acute 1:H  |  |  |  |  |  |  |  |
| -         |   |   | 1400   | DEAQU  | Skin Sono 1 H21  |  |  |  |  |
|           |   | 1,2-benzisothiazol-3(2H)-one<br>CAS: 2634-33-5, EC: 220-120-9, REACH: 01-212076154  | 0-60   | REACH  | Skin Sens. 1, H31<br>C ≥0,05 °   |  |  |  |  |
|           |   | CLP: Danger: Acute Tox. (oral) 4:H302 (ATE=490 mg/kg)   |  |  |  |  |  |  |  |
|           | I   | Eye Dam. 1:H318   Skin Sens. 1:H317   Aquatic Acute 1:F   | H400 (M=10)  |  |  |  |  |  |  |
| Ī         | C < 0,0015 %  | Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3-one  | e [EC 247-500-7]   | ATP13  | Skin Corr. 1C, H31   |  |  |  |  |
|           |   | and 2-methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)   |  |  | C ≥0,6<br>Skin Irrit. 2, H31   |  |  |  |  |
|           |   | CAS: 55965-84-9, EC: 611-341-5<br>CLP: Danger: Acute Tox. (inh.) 2:H330 (ATE=50 mg/m3)  | Aguta Tax (akin)   |  | 0,06 % ≤ C < 0,6   |  |  |  |  |
|           |   | 2:H310 (ATE=140 mg/kg)   Acute Tox. (oral) 3:H301 (ATE  |  |  | Eye Dam. 1, H31<br>C ≥0,6  |  |  |  |  |
|           |   | Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute 1:H400  | ) (M=100) Aquatic  |  | Eye Irrit. 2, H31<br>0,06 % ≤ C < 0,6  |  |  |  |  |
|           |   | Chronic 1:H410 (M=100)   EUH071   Skin Sens. 1A:H317  | (Note B)   |  | Skin Sens. 1A, H31   |  |  |  |  |
| -         |   |   |  |  | C ≥0,0015  |  |  |  |  |
|           | Impurities:   |   |  |  |  |  |  |  |  |
|           |   | components or impurities which will influence the classific   | cation of the product.   |  |  |  |  |  |  |
|           | Stabilizers:  |   |  |  |  |  |  |  |  |
|           | None.<br>Reference to other sections:   |   |  |  |  |  |  |  |  |
|           |   | ee sections 8, 11, 12 and 16.   |  |  |  |  |  |  |  |
|           |   | ERY HIGH CONCERN (SVHC):  |  |  |  |  |  |  |  |
|           | List updated by ECHA  | · /   |  |  |  |  |  |  |  |
|           |   | ibject to authorisation, included in Annex XIV of Reg   | ulation (EC) no. 1907/20   | <u>06:</u>   |  |  |  |  |  |
|           | None.   | -   |  |  |  |  |  |  |  |
|           | Substances SVHC ca  | andidate to be included in Annex XIV of Regulation (  | <u>EC) no. 1907/2006:</u>  |  |  |  |  |  |  |
|           | None.   |   |  |  |  |  |  |  |  |
|           |   | CCUMULABLE AND TOXIC PBT, OR VERY PERSIS  | STENT AND VERY BIOA  | CCUMULAB   | <u>LE VPVB</u>   |  |  |  |  |
|           | SUBSTANCES:   | ences that fulfil the DDT/ (D) D suiteria   |  |  |  |  |  |  |  |
|           |   | ances that fulfil the PBT/vPvB criteria.<br>uded in the (EU) REGULATION 2019/1021~2020/78   | 4 on persistent organic n  | ollutante  |  |  |  |  |  |
|           | None.   |   | Heron persistent organic p   | oliutants.   |  |  |  |  |  |
|           | 1 4: FIRST AID MEASUF   | 2FS   |  |  |  |  |  |  |  |
| .1        |   | IRST AID MEASURES:  |  |  |  |  |  |  |  |
|           |   | occur after exposure, so that in case of direct exposure t  | to the product, when in dou  | ht or when s   | mntoms persist   |  |  |  |  |
| . '       |   |   |  | bt, or when sy   | inploms persist,   |  |  |  |  |
| . 1       |   | tention.Never give anything by mouth to an unconscious  | •  |  |  |  |  |  |  |
|           |   |   |  | leasures   |  |  |  |  |  |
| . 1       | Route of exposure   | Symptoms and effects, acute and delayed   | Description of first-aid m   | 10000100   |  |  |  |  |  |
|           | Route of exposure   | Symptoms and effects, acute and delayed   | -  |  | fer the person   |  |  |  |  |
|           |   |   | Description of first-aid m<br>Should there be any syn<br>affected to the open air.   |  | fer the person   |  |  |  |  |
|           | Route of exposure   | Symptoms and effects, acute and delayed<br>It is not expected that symptoms will occur under  | Should there be any syn<br>affected to the open air.<br>Remove contaminated c  | nptoms, trans<br>clothing.Wash   | thoroughly the   |  |  |  |  |
|           | Route of exposure   | Symptoms and effects, acute and delayed<br>It is not expected that symptoms will occur under<br>normal conditions of use.   | Should there be any syn<br>affected to the open air.<br>Remove contaminated o<br>affected area with plenty   | nptoms, trans<br>clothing.Wash<br>/ of cold or luk   | thoroughly the<br>kewarm water and   |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:   | Symptoms and effects, acute and delayed<br>It is not expected that symptoms will occur under<br>normal conditions of use.<br>It is not expected that symptoms will occur under<br>normal conditions of use.   | Should there be any syn<br>affected to the open air.<br>Remove contaminated o<br>affected area with plenty<br>neutral soap, or use a su  | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin clo   | thoroughly the<br>kewarm water and<br>eanser.  |  |  |  |  |
|           | Route of exposure   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.   | Should there be any syn<br>affected to the open air.<br>Remove contaminated o<br>affected area with plenty<br>neutral soap, or use a su<br>Remove contact lenses.  | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cl<br>Rinse eyes co   | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by   |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:   | Symptoms and effects, acute and delayed<br>It is not expected that symptoms will occur under<br>normal conditions of use.<br>It is not expected that symptoms will occur under<br>normal conditions of use.   | Should there be any syn<br>affected to the open air.<br>Remove contaminated o<br>affected area with plenty<br>neutral soap, or use a su<br>Remove contact lenses.<br>irrigation with plenty of o   | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin clu<br>Rinse eyes co<br>clean, fresh wa   | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the                      |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.   | Should there be any syn<br>affected to the open air.<br>Remove contaminated o<br>affected area with plenty<br>neutral soap, or use a su<br>Remove contact lenses.  | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin clu<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons                                     | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:  | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.  | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a su<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting<br>aspiration.Keep the pati                                    | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin clo<br>Rinse eyes co<br>clean, fresh wa<br>persists, cons<br>, due to the ris                 | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
| .2        | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:  | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause   | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a su<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting<br>aspiration.Keep the pati                                    | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin clo<br>Rinse eyes co<br>clean, fresh wa<br>persists, cons<br>, due to the ris                 | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:<br><u>MOST IMPORTANT</u><br>The main symptoms an   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D ad effects are indicated in sections 4.1 and 11.1   | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a syn<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting,<br>aspiration.Keep the pation<br>DELAYED:                    | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cli<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons<br>due to the ris<br>ent at rest.   | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
|           | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:<br><u>MOST IMPORTANT</u><br>The main symptoms an   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D   | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a syn<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting,<br>aspiration.Keep the pation<br>DELAYED:                    | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cli<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons<br>due to the ris<br>ent at rest.   | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
| .2        | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:<br><u>MOST IMPORTANT</u><br>The main symptoms an   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D ad effects are indicated in sections 4.1 and 11.1   | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a syn<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting,<br>aspiration.Keep the pation<br>DELAYED:                    | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cli<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons<br>, due to the ris<br>ent at rest. | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
| .2        | Route of exposure<br>Inhalation:<br>Skin:<br>Eyes:<br>Ingestion:<br><u>MOST IMPORTANT</u><br>The main symptoms an<br><u>INDICATION OF ANY</u><br><u>Notes to physician:</u><br>Treatment should be di | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D of effects are indicated in sections 4.1 and 11.1         TIMMEDIATE MEDICAL ATTENTION AND SPECIA         rected at the control of symptoms and the clinical condition              | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a sy<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting<br>aspiration.Keep the pation<br>DELAYED:<br>ALTREATMENT NEEDE | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cli<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons<br>, due to the ris<br>ent at rest. | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |
| .2        | Route of exposure Inhalation: Skin: Eyes: Ingestion: MOST IMPORTANT The main symptoms an INDICATION OF AN Notes to physician:   | Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D of effects are indicated in sections 4.1 and 11.1         (IMMEDIATE MEDICAL ATTENTION AND SPECIA)         rected at the control of symptoms and the clinical condition ndications: | Should there be any syn<br>affected to the open air.<br>Remove contaminated of<br>affected area with plenty<br>neutral soap, or use a sy<br>Remove contact lenses.<br>irrigation with plenty of of<br>eyelids apart.If irritation<br>Do not induce vomiting<br>aspiration.Keep the pation<br>DELAYED:<br>ALTREATMENT NEEDE | nptoms, trans<br>clothing.Wash<br>/ of cold or luk<br>uitable skin cli<br>Rinse eyes ca<br>clean, fresh wa<br>persists, cons<br>, due to the ris<br>ent at rest. | thoroughly the<br>kewarm water and<br>eanser.<br>opiously by<br>ater, holding the<br>sult a physician. |  |  |  |  |

| Т.     |   | Code : 1656   |  |                                       |
|--------|---|---|--|---------------------------------------|
| ersior | n: 3 Re                                       | evision: 11/03/2024   | Previous revision: 23/12/2022  | Date of printing: 11/03/202           |
| ECTION | N 5: FIREFIGHTING MI                          | EASURES   |  |                                       |
| 5.1    | EXTINGUISHING N                               | <u>IEDIA:</u>   |  |                                       |
|        |   | surroundings, all extinguishing agents  |  |                                       |
| 5.2    |   | S ARISING FROM THE SUBSTA   |  | anida. Oadaan dianida                 |
|        |   |   | , hazardous products may be produced: carbon mon<br>ydrochloric acid.Exposure to combustion or decomp  |                                       |
| i.3    | ADVICE FOR FIRE                               | FIGHTERS:   |  |                                       |
|        | Special protective e                          | equipment:  |  |                                       |
|        | protective glasses or sheltered position or t | face masks and boots.If the fire-proo<br>from a safe distance.The standard EN | hing may be required, appropriate independent brea<br>of protective equipment is not available or is not bein<br>N469 provides a basic level of protection for chemica | g used, combat fire from a            |
|        |   |   | sources of heat or fire.Bear in mind the direction of the  | ne wind.Do not allow fire-            |
| CTION  | N 6: ACCIDENTAL REL                           | EASE MEASURES   |  |                                       |
| .1     | PERSONAL PREC                                 | AUTIONS, PROTECTIVE EQUIP   | MENT AND EMERGENCY PROCEDURES:   |                                       |
|        |   |   | ours.Keep people without protection in opposition to   | the wind direction.                   |
| .2     | ENVIRONMENTAL                                 |   |  |                                       |
|        | lakes, rivers or sewag                        | ges, inform the appropriate authorities                                       | ater and soil.In the case of large scale spills or when<br>s in accordance with local regulations.   | the product contaminates              |
| 5.3    | -   | ATERIAL FOR CONTAINMENT A   |  | to ) Koon the remains in a            |
|        | closed container.                             | spills with absorbent materials (sawd   | ust, earth, sand, vermiculite, diatomaceous earth, et  | ic). Keep the remains in a            |
| 6.4    | REFERENCE TO C                                | THER SECTIONS:  | <u> </u>   |                                       |
|        |   | on in case of emergency, see section  | 1.   |                                       |
|        |   | fe handling, see section 7.   |  |                                       |
|        |   | s and personal protection measures,   |  |                                       |
|        |   | blow the recommendations in section   | 113.   |                                       |
| CTION  | N 7: HANDLING AND S                           |   |  |                                       |
| .1     |   | OR SAFE HANDLING:   |  |                                       |
|        |   | ing legislation on health and safety a  | t work.  |                                       |
|        | - General recomme                             |   |  |                                       |
|        |   | kage or escape.Keep the container tig   |  |                                       |
|        |   | <u>s for the prevention of fire and exp</u>                                   |  | <b>.</b>                              |
|        |   |   | nd does not sustain the combustion reaction by oxyge of Directive 2014/34/EU concerning equipment and  |                                       |
|        |   | explosive atmospheres.  | 3 of Directive 2014/34/EO concerning equipment and   | a protective systems intende          |
|        |   | s for the prevention of toxicologica  | ıl risks:  |                                       |
|        |   |   | wash hands with soap and water. For exposure cont  | rols and personal protection          |
|        | measures, see sectio                          | <b>e</b>  |  | · · · · · · · · · · · · · · · · · · · |
|        |   | s for the prevention of environmen  |  |                                       |
|        |   | •   | se of accidental spillage, follow the instructions indic   | cated in section 6.                   |
| .2     |   | SAFE STORAGE, INCLUDING A   |  |                                       |
|        |   | to avoid leakages, the containers, af   | ch of children. Keep away from sources of heat. If po<br>fter use, should be closed carefully and placed in a v  |                                       |
|        | - Class of store:                             |   |  |                                       |
|        | According to current I                        | -   |  |                                       |
|        | - Maximum storage                             | period:   |  |                                       |
|        | # 24 Months.                                  |   |  |                                       |
|        | - Temperature inter                           |   |  |                                       |
|        | min:5 °C, max:40 °C                           |   |  |                                       |
|        | - Incompatible mate                           | izing agents, acids, alkalis.   |  |                                       |
|        | - Type of packaging                           |   |  |                                       |
|        | According to current I                        |   |  |                                       |
|        | -   | /eso III): Directive 2012/18/EU:  |  |                                       |
|        |   | ict for non industrial use).  |  |                                       |
|        | SPECIFIC END US                               |   |  |                                       |
| 3      |   |   |  |                                       |
| .3     | For the use of this pro                       |   | art from that already indicated are not available.   |                                       |

|  | /al   | DUEPOL ACQUA SUELO  | S SATINADO  |   |  |  |  |  |
|--|---|---|---|---|--|--|--|--|
| pi   | nturas  | Code : 1656   |   |   |  |  | Datasta  |  |
|  |   | sion: 11/03/2024<br>DLS/PERSONAL PROTE  | CTION   | Pi  | revious revision:  | 23/12/2022   | Date of p  | orinting: 11/03/20   |
| CONTROL F  |   |   | CHON  |   |  |  |  |  |
| effectiveness<br>made to EN68<br>exposure to c<br>determination  | of the venti<br>89, EN1404<br>chemical an<br>of dangero   | edients with exposure lin<br>lation or other control me<br>2 and EN482 standard c<br>d biological agents. Refe<br>ous substances.<br>POSURE LIMIT VALU  | easures and/or the i<br>oncerning methods<br>rence should be als  | necessity to<br>for assesing  | use respiratory<br>g the exposure  | / protective equipsion by inhalation to  | ipment. Refe   | rence should<br>gents, and   |
| EH40/2005 W<br>Kingdom) 201  |   | d Y   | ′ear   WEL-TWA  |   | WEL-STEL   |  | Remarks  |  |
| 1,2-benzisoth  |   | 000   | ppm   | mg/m3<br>0,1  |  | mg/m3  |  | Recommend  |
| 1,2-benzisoth  | . ,   |   |   | 0,1   |  | -  |  | Recommend  |
| Reaction mas<br>-isothiazolin-3  | ss of 5-chloi<br>3-one [EC 2  | ro-2-methyl-2H<br>47-500-7] and<br>-one [EC 220-  |   | 0,08  |  | 0,23   | 5  | Recommend  |
| Derived no-ef  | ed<br><u>NO-EFFE(</u><br>ffect level ([   | <u>CT LEVEL (DNEL):</u><br>DNEL) is a level of exposi<br>L values may differ from   |   |   |  |  |  |  |
| recommended<br>health, the OE  | d by a parti<br>EL values a   | cular company, a governi<br>re derived by a process o   | ment regulatory age   | ency or an or   | ganization of e  | experts. Althoug   | h considered   |  |
| - DERIVED NO<br>Systemic effect  |   | EVEL, WORKERS:-   | DNEL Inhalation<br>mg/m3  |   | DNEL Cutaneo<br>mg/kg bw/d   | ous  | DNEL Oral<br>mg/kg bw/d  |  |
| Systemic ellect  | is, acute and   | CHIONIC.  |   |   |  |  |  |  |
| 1.2-benzisothia  | azol_3(2H)_or   | 0   | s/r (a)   | 6 81 (c)  | s/r (a)  | 0.966 (c)  | - (a)  | - (c)  |
| one [EC 247-50   | of 5-chloro-2<br>00-7] and 2-r  | e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one  | s/r (a)<br>- (a)  | 6,81 (c)<br>- (c)   | s/r (a)<br>- (a)   | 0,966 (c)<br>- (c)   | - (a)<br>- (a)   | - (c)<br>- (c)   |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]  | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)   | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one   |   | , .,  | . ,  | ,  |  | - (c)  |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia   | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE   | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one   | - (a)   | - (c)   | - (a)  | - (c)<br>- (c)   | - (a)  |  |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia  | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE<br>and chronic:<br>azol-3(2H)-or  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, WORKERS:- Local<br>e  | - (a)<br>- (a)<br>DNEL Inhalation   | - (c)   | - (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)  | - (c)<br>- (c)<br><u>- us</u><br>a/r (c)   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)  | - (c)<br>- (c)   |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50   | 6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, WORKERS:- Local   | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3   | - (c)<br>- (c)  | - (a)<br><u> DNEL Cutaneo</u><br>mg/cm2  | - (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2   | - (C)  |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass   | 6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)   | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one   | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>s/r (a)  | - (c)<br>- (c)<br>s/r (c)   | - (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)  | - (c)<br>- (c)<br><u>- us</u><br>a/r (c)   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)  | - (c)<br>- (c)   |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>POPULATION:   | 6 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>D-EFFECT LE<br>- Systemic e  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:  | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3  | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/kg bw/d   | - (c)<br>- (c)<br><u>uus</u><br>a/r (c)<br>- (c)<br>- (c)<br><u>uus</u>                                  | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d   | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)  |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>POPULATION:<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50   | 6 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>-EFFECT LE<br>azol-3(2H)-or<br>-EFFECT LE<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>-EFFECT LE<br>-Systemic e<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>00-7] and 2-r   | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:  | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>s/r (a)<br>- (a)<br><u>DNEL Inhalation</u>   | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u>   | - (c)<br>- (c)<br><u>- (c)</u><br>- (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u>   | - (c)<br>- (c)<br>- (c)  |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>POPULATION:<br>1,2-benzisothia<br>Reaction mass   | 6 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>-EFFECT LE<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>-EFFECT LE<br>- Systemic e<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)   | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one  | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>- (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>s/r (a)   | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)<br>1,2 (c)  | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/kg bw/d<br>s/r (a)  | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)                                     | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)  | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>s/r (c)                                   |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>POPULATION:<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- LOCAL EFFE<br>effects, acute a  | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>)-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>6 of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>CTS, ACUTE<br>and chronic:  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>E AND CHRONIC:- Local  | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3   | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>- (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/kg bw/d<br>s/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2  | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)                   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br><u>DNEL Eyes</u><br>mg/cm2 | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)          |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>POPULATION:<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- LOCAL EFFE<br>effects, acute a<br>1,2-benzisothia   | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>)-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>[ (3:1)<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>cTTS, ACUTE<br>and chronic:<br>azol-3(2H)-or  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>E AND CHRONIC:- Local<br>e                                       | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)  | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>- (c)<br>s/r (c)  | - (a)<br>- (a)<br>DNEL Cutaneo<br>mg/cm2<br>a/r (a)<br>- (a)<br>DNEL Cutaneo<br>mg/kg bw/d<br>s/r (a)<br>- (a)<br>DNEL Cutaneo<br>mg/cm2<br>a/r (a)<br>- (a)   | - (c)<br>- (c)          | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)                    | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)          |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 247-50]  | acol-3(2H)-or<br>azol-3(2H)-or<br>-EFFECT LE<br>azol-3(2H)-or<br>-EFFECT LE<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>color 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>color 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>color 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>color 5-chloro-2<br>00-7] and 2-r<br>azol-3(2H)-or<br>color 5-chloro-2<br>00-7] and 2-r  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>EVEL, GENERAL<br>ffects, acute and chronic:<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>E AND CHRONIC:- Local  | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3   | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>- (c)<br>- (c)   | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2<br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/kg bw/d<br>s/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm2  | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)                   | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br><u>DNEL Eyes</u><br>mg/cm2 | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)          |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- LOCAL EFFE<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]  | 6 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>-EFFECT LE<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>5 of 5-chloro-2<br>200-7] and 2-r<br>] (3:1)  | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>E AND CHRONIC:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>S/r (a)  | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>- (c)<br>s/r (c)  | - (a)<br>- (a)<br>DNEL Cutaneo<br>mg/cm2<br>a/r (a)<br>- (a)<br>DNEL Cutaneo<br>mg/kg bw/d<br>s/r (a)<br>- (a)<br>DNEL Cutaneo<br>mg/cm2<br>a/r (a)<br>- (a)   | - (c)<br>- (c)          | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)                    | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)          |
| Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>- DERIVED NO<br>effects, acute a<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 220-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 20-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 20-239-6]<br>1,2-benzisothia<br>Reaction mass<br>one [EC 247-50<br>[EC 20-239-6]<br>1,2-benzisothia | of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>-EFFECT LE<br>and chronic:<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>cTS, ACUTE<br>and chronic:<br>azol-3(2H)-or<br>cTS, ACUTE<br>and chronic:<br>azol-3(2H)-or<br>of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>s of 4-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>s of 5-chloro-2<br>00-7] and 2-r<br>] (3:1)<br>azol-3(2H)-or<br>s of 4-chloro-2<br>00-7] and 2-r<br>] (3:1) | 2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>EVEL, WORKERS:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one<br>e<br>E AND CHRONIC:- Local<br>e<br>2-methyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazolin-3-<br>nethyl-2H-isothiazol-3-one | - (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3<br>s/r (a)<br>- (a)<br><u>DNEL Inhalation</u><br>mg/m3 | - (c)<br>- (c)<br>s/r (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>1,2 (c)<br>- (c)<br>- (c)<br>s/r (c)<br>- (c)<br>- (c)<br>- (c) | - (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm <sup>2</sup><br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/kg bw/d<br>S/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm <sup>2</sup><br>a/r (a)<br>- (a)<br><u>DNEL Cutaneo</u><br>mg/cm <sup>2</sup><br>a/r (a)<br>- (a) | - (c)<br>- (c) | - (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/kg bw/d<br>2 (a)<br>- (a)<br><u>DNEL Eyes</u><br>mg/cm2<br>m/r (a)<br>- (a)           | - (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c)<br>- (c) |

| <mark>  i</mark> s  | aval   | DUEPOL ACQUA SUELOS<br>Code : 1656  | SATINADO  |   |  |   |  |  |
|---|--|---|---|---|--|---|--|--|
| ersion: 3   | Revi   | sion: 11/03/2024  |   | Pr  | revious revision: 23/  | 12/2022   | Date of p  | rinting: 11/03/20                              |
| isothia   | zolin-3-one [EC  | nloro-2-methyl-2H-<br>247-500-7] and 2-<br>3-one [EC 220-239-6]   |   | -   |  | -   |  | -  |
|   | nzisothiazol-3(2   | ,   |   | -   |  | -   |  | -  |
| <u>- WAST</u><br>AND SE<br>WATER  | EDIMENTS IN F  | <u>TMENT PLANTS (STP)</u><br>RESH- AND MARINE   | PNEC STP<br>mg/l  |   | PNEC Sediments<br>mg/kg dw/d   |   | PNEC Sedim<br>mg/kg dw/d                         | <u>ents</u>                                    |
| 1,2-ber<br>Reaction<br>isothiaz<br>methyl-<br>(3:1)                                   | nzisothiazol-3(2<br>on mass of 5-cl<br>zolin-3-one [EC<br>-2H-isothiazol-3 | hloro-2-methyl-2H-<br>247-500-7] and 2-<br>3-one [EC 220-239-6]   |   | 1.03<br>-   |  | 0.0499<br>-                                       |  | 0.00499<br>-                                   |
|   | nzisothiazol-3(2   | -   |   | -   |  | -   |  | -  |
| TERRE   |  | <u>ECT CONCENTRATION.</u><br><u>IISMS:- Air, soil and</u><br>d humans <u>:</u>  | PNEC Air<br>mg/m3   |   | <u>PNEC Soil</u><br>mg/kg dw/d   |   | PNEC Oral<br>mg/kg dw/d                          |  |
| Reaction isothia  | zolin-3-one [EC  | 2H)-one<br>hloro-2-methyl-2H-<br>2 247-500-7] and 2-<br>3-one [EC 220-239-6]  |   | s/r<br>-  |  | 3<br>-  |  | n/b<br>-                                       |
|   | nzisothiazol-3(2   | PH)-one   |   | -   |  | -   |  | -  |
| n/b - Pl<br>s/r - PN  | NEC not derive   | ble (without data of registra<br>ed (not bioaccumulative po<br>d (not identified hazard).   | ation REACH).<br>tential).  |   |  |   | 1  |  |
|   | EERING MEA   |   |   |   |  |   |  |  |
| Avoid th<br><u>- Prote</u><br>It is recu-<br><u>- Prote</u><br>It is recu-<br>exposed | ction of hands<br>commended to in<br>d areas of the sk                     | <u>tory system:</u><br>/apours.<br><u>nd face:</u><br>stall water taps or sources w<br><u>and skin:</u><br>stall water taps or sources w<br>in.Barrier creams should no | ith clean water clos<br>t be applied once e                                       | e to the w<br>e to the w<br>xposure ha              | rorking area.<br>rorking area.Barrie<br>as occurred.                           |   |  |  |
| As a ge<br>with the<br>charact  | neral measure of corresponding   | POSURE CONTROLS: R<br>on prevention and safety in the<br>marking. For more information<br>PE, protection class, marking<br>PE.  | ne work place, we re<br>on on personal prot                                       | ecommeno<br>ective equ                              | d the use of a bas<br>uipment (storage,  | use, cleani                                       | ing, maintenan                                   | ice, type and                                  |
| Mask:   |  | # A-type filter mask (b<br>✓ than 65°C (EN14387)<br>ppm, Class 3: high ca<br>class must be selected<br>in accordance with th  | Class 1: low capa<br>pacity up to 1000<br>d depending on the<br>specifications su | acity up to<br>0 ppm.In<br>ne type ar<br>upplied by | o 1000 ppm, Cla<br>order to obtain a<br>nd concentratior<br>y the filter produ | iss 2: med<br>a suitable<br>n of the con<br>cers. | lium capacity<br>protection lev<br>ntaminating a | up to 5000<br>rel, the filter<br>agents presen |
| Safety  | goggles:   | Safety goggles design<br>(EN166).Clean daily a<br>manufacturer.   |   |   |  |   |  |  |
| Face s  | hield:   | No.   |   |   |  |   |  |  |
| Gloves  | :  | # Gloves resistant ag<br>✓ expected, gloves of p<br>min.When short conta  | rotection level 5 o   | r higher s<br>ct is expe                            | should be used,<br>cted, use gloves  | with a brea<br>s with a pro                       | akthrough tim<br>otection level                  | ne of >240                                     |

| n (ÈC) No. 1907/2006 and Regulation (EU)  | No. 2020/878 (Language:EN  |
|---|--|
| DUEPOL ACQUA SUELOS SATIN<br>Code : 1656  | IADO   |
| Revision: 11/03/2024  | Previous revision: 23/12/2022 Date of printing: 11/03/2024   |
| No.   |  |
| No.   |  |
| No.   |  |
| he product is handled at room temperatu<br>ITAL EXPOSURE CONTROLS:<br>ge in the environment. Avoid any release<br>soil:<br>nation of soil.<br>escape into drains, sewers or water course<br>agement Act:<br>as not contain any substance included in the<br>13/39/EU.<br>the atmosphere:<br>tility, emissions to the atmosphere while the<br>ready for use*):<br>he Directive 2004/42/EC, on the limitation<br>ES (defined in the Directive 2004/42/EC, A<br>ady for use*): (DUEPOL ACQUA SUELO<br>0 / 7 in volume): 6,6 g/l* (VOC max.140 g/<br>Linstallations):<br>used in an industrial installation, it must be<br>assions of volatile compounds due to the u | nto the atmosphere.<br>es.<br>he list of priority substances in the field of water policy under Directive<br>andling and use may result. Avoid any release into the atmosphere.<br>of emissions of volatile compounds due to the use of organic solvents: PAINTS<br>unnex I.1): Emission subcategory j) Two-pack performance coating, water-borne.<br>S SATINADO Cod. 1656 / ENDURECEDOR DUEPOL ACQUA MATE SEDOSO  |
|   | DUEPOL ACQUA SUELOS SATIN         Code : 1656         Revision: 11/03/2024         No.         No.         No.         No.         No.         No.         No.         No.         Italian         No.         No.         No.         Italian         No.         No.         Italian         No.         No.         Italian         No.         Italian         No.         No.         No.         No.         No.         Italian         No.         Italian         Revision: tanaded at room temperature         Italian         No.         Italian         No.         Italian         No.         Italian         Italian         Italian         Italian         No.         Italian         Italian         Italian         Itanos of soil.         Italian     < |

|                | pinturas                            | DUEPOL ACQUA SUELOS SATINAL<br>Code : 1656 | 00  |                            |
|----------------|-------------------------------------|--|---|----------------------------|
| rsion: 3       | Rev                                 | vision: 11/03/2024                         | Previous revision: 23/12/2022                           | Date of printing: 11/03/20 |
| TION 9: PHY    | SICAL AND CH                        | IEMICAL PROPERTIES                         |   |                            |
| INFO           | RMATION ON                          | BASIC PHYSICAL AND CHEMICA                 | L PROPERTIES:   |                            |
|                | arance                              |  |   |                            |
|                | al state:                           |  | Liquid  |                            |
| Colour         |                                     |  | See the colour in the package                           |                            |
| Odour          | :                                   |  | Characteristic  |                            |
| Odour          | threshold:                          |  | Not available (mixture).                                |                            |
| Chano          | ge of state                         |  |   |                            |
| Freezi         | ng point:                           |  | Not available (mixture).                                |                            |
| Initial b      | oiling point:                       |  | > 100* °C at 760 mmHg                                   |                            |
|                | <u>nmability:</u>                   |  |   |                            |
| Flashp         |                                     |  | Not flammable   |                            |
|                |                                     | lity or explosive limits:                  | Not available   |                            |
| -              | nition temperatu                    | ire:                                       | Not applicable (do not sustain combustion).             |                            |
| <u>Stabili</u> |                                     |  |   |                            |
|                | position temper                     | ature:                                     | 1,600,00* °C  |                            |
| <u>pH-va</u>   | lue                                 |  |   |                            |
| pH:            |                                     |  | 10 at 20°C  |                            |
| - Visc         |                                     |  |   |                            |
|                | nic viscosity:                      |  | Not available.  |                            |
|                | atic viscosity:                     |  | Not available.  |                            |
|                | <u>ıbility(ies):</u>                |  |   |                            |
|                | ity in water                        |  | Miscible  |                            |
|                | lubility:                           |  | Not applicable (inorganic product).                     |                            |
|                | on coefficient: n-                  | octanol/water:                             | Not applicable (mixture).                               |                            |
| - Vola         |                                     |  |   |                            |
|                | r pressure:                         |  | 17,535* mmHg at 20°C                                    |                            |
|                | r pressure:                         |  | 12,113* kPa at 50°C                                     |                            |
|                | ration rate:                        |  | Not available (lack of data).                           |                            |
| Densi          |                                     |  | 4 404* -+ 00/400  | Deletine meter             |
|                | e density:                          |  | 1,194* at 20/4°C  | Relative water             |
|                | e vapour densit<br>le characteristi |  | Not available.  |                            |
| Particle       |                                     |  | Not applicable.   |                            |
|                |                                     |  | Not applicable.   |                            |
|                | <u>losive propertie</u><br>ailable. | <u>25.</u>                                 |   |                            |
|                | dizing propertie                    |  |   |                            |
|                | assified as oxidiz                  |  |   |                            |
| INOL CIE       |                                     |  |   |                            |
| *Estim         | ated values bas                     | ed on the substances composing the         | mixture.  |                            |
|                | R INFORMAT                          |  |   |                            |
|                |                                     | g physical hazard classes                  |   |                            |
|                | ditional informati                  |  |   |                            |
|                | security featur                     |  |   |                            |
|                | supply):                            | <u></u>                                    | 0.5 % Weight  |                            |
|                | supply):                            |  | 6,0 g/l   |                            |
| Nonvo          |                                     |  | 41,72 * % Weight  | 1h. 60⁰C                   |
|                |                                     |  |   |                            |
|                | lues indicated d                    | lo not always coincide with product sp     | ecifications. The data for the product specifications c | an be found in the         |
| The va         |                                     |  | on concerning physical and chemical properties relate   | ed to safety and           |
| corres         |                                     |  |   |                            |

| К      |  | DUEPOL ACQUA SUELO<br>Code : 1656  | DS SATINADO  |   |   |
|--------|--|--|--|---|---|
| ersior | n: 3 Rev   | ision: 11/03/2024  | Pre  | evious revision: 23/12/2022   | Date of printing: 11/03/20  |
|        | N 10: STABILITY AND R  | EACTIVITY  |  |   |   |
| 10.1   | REACTIVITY:  |  |  |   |   |
|        | - Corrosivity to meta  | ls:  |  |   |   |
|        | It is not corrosive to me  | etals.   |  |   |   |
|        | - Pyrophorical prope   | <u>rties:</u>  |  |   |   |
|        | It is not pyrophoric.  |  |  |   |   |
| 0.2    | CHEMICAL STABILI   |  |  |   |   |
| 0.0    | Stable under recommended storage and ha  |  |  |   |   |
| 0.3    |  | action with oxidizing agent  |  |   |   |
| 0.4    | CONDITIONS TO AV   |  |  |   |   |
| 0.1    | - Heat:  |  |  |   |   |
|        | Keep away from source  | es of heat.  |  |   |   |
|        | - Light:   |  |  |   |   |
|        | If possible, avoid direct  | contact with sunlight.   |  |   |   |
|        | <u>- Air:</u>  |  |  |   |   |
|        |  | cted by exposure to air, bu  | it should not be left the containers   | s open.   |   |
|        | <u>- Pressure:</u><br>Not relevant.  |  |  |   |   |
|        | - Shock:   |  |  |   |   |
|        |  | sitive to shocks, but as a re  | ecommendation of a general natu  | ire should be avoided humps   | and rough handling to ave   |
|        |  |  | en the product is handled in large   |   |   |
| ).5    | INCOMPATIBLE MA  | TERIALS:   |  |   |   |
|        |  | ing agents, acids, alkalis.  |  |   |   |
| 0.6    |  | MPOSITION PRODUC   |  |   |   |
|        | As consequence of the<br>halogenated compound  |  | rdous products may be produced   | l: nitrogen oxides, sulfur oxide  | es, hydrochloric acid,  |
|        | N 11: TOXICOLOGICAL  |  |  |   |   |
|        |  |  | preparation is available. The to   | vicele ricel close if in the for  |   |
| 1.1    |  |  | tion method of the Regulation  | . ,   | 692 (CLP).  |
|        |  |  |  | (20) 110 1212/2000.   |   |
|        | ACUTE TOXICITY:  |  |  |   |   |
|        | Dose and lethal conc   |  | DL50 (OECD401)   | DL50 (OECD402   |   |
|        | Dose and lethal conc<br>for individual ingredie  | nts:   | DL50 (OECD401)<br>mg/kg bw Ora   | DL50 (OECD402<br>mg/kg bw Cutaneous   | s mg/m3·4h Inhalat  |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(2   | nts:<br>2H)-one  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Rat  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra  | s mg/m3·4h Inhalat<br>t   |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(2<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC  | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-   | DL50 (OECD401)<br>mg/kg bw Ora   | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra  | s mg/m3·4h Inhalat<br>t   |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(2<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-   | nts:<br>2H)-one<br>hloro-2-methyl-2H-  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Rat  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra  | s mg/m3·4h Inhalat<br>t   |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(2<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra  | s mg/m3·4ȟ Inhalat<br>t<br>t > 1230 I   |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3  | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra   | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra   | s mg/m3·4h Inhalat<br>t<br>t > 1230 l<br>t > 2050 l   |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>Estimates of acute to   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>ATE  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra   | s mg/m3·4h Inhalat<br>t<br>t > 1230 l<br>t > 2050 l<br>=A   |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(2<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(2<br>Estimates of acute to<br>for individual ingredie   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>ATE<br>mg/kg bw Ora   | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous   | s mg/m3·4h Inhalat<br>t<br>t > 1230 l<br>t > 2050 l<br>=A   |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(2<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(2<br>Estimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(2   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Rat<br>74,9 Rat<br>1020 Rat<br>1020 Rat<br>ATE<br>mg/kg bw Ora<br>490  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous  | s mg/m3·4h Inhalat<br>t<br>t<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat  |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(<br>Estimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>ATE<br>mg/kg bw Ora   | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous  | s mg/m3·4h Inhalat<br>t<br>t<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat  |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(<br>Estimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Rat<br>74,9 Rat<br>1020 Rat<br>1020 Rat<br>ATE<br>mg/kg bw Ora<br>490  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous  | s mg/m3·4h Inhalat<br>t<br>t<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat  |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(<br>Estimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-  | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Rat<br>74,9 Rat<br>1020 Rat<br>1020 Rat<br>ATE<br>mg/kg bw Ora<br>490  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous  | s mg/m3·4h Inhalat<br>t > 1230 F<br>t > 2050 F<br>t > 2050 F<br>S mg/m3·4h Inhalat  |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>Estimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>MTE<br>mg/kg bw Ora<br>490<br>74,9  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140  | s mg/m3·4h Inhalat<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat<br>- *>  |
|        | Dose and lethal concerns         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         For individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         (3:1)         1,2-benzisothiazol-3(3         (3:1)         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>2 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>2 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>acute toxicity correspondition<br>on of the ATE for classification   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>ATE<br>mg/kg bw Ora<br>490<br>74,9  | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140<br>see GHS/CLP Table 3.1.2). The<br>mponents and do not represe  | s mg/m3·4h Inhalat<br>t > 1230 I<br>t > 2050 I<br>s mg/m3·4h Inhalat<br>o *><br>- hese values are designed<br>ent test results.   |
|        | Dose and lethal conce<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>For individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>(*) - Point estimates of<br>be used in the calculati<br>(-) - The components th   | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>2 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>2 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>acute toxicity correspondit<br>on of the ATE for classifica<br>nat are assumed to have n   | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>MTE<br>mg/kg bw Ora<br>490<br>74,9<br>*567<br>ng to the classification category (<br>ation of a mixture based on its co   | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140<br>see GHS/CLP Table 3.1.2). The<br>mponents and do not represe<br>shold of category 4 for the cor                         | s mg/m3·4h Inhalat<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat<br>A mg/m3·4h Inhalat<br>> *><br>hese values are designed<br>ent test results.<br>rresponding exposure rout<br>NOAEC Inhalat |
|        | Dose and lethal conc<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>Festimates of acute to<br>for individual ingredie<br>1,2-benzisothiazol-3(3<br>Reaction mass of 5-c<br>isothiazolin-3-one [EC<br>methyl-2H-isothiazol-<br>(3:1)<br>1,2-benzisothiazol-3(3<br>(*) - Point estimates of<br>be used in the calculati<br>(-) - The components th<br>are ignored.  | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>acute toxicity correspondin<br>on of the ATE for classification<br>and are assumed to have not an                | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>1020 Ra<br>MTE<br>mg/kg bw Ora<br>490<br>74,9<br>*567<br>ng to the classification category (<br>ation of a mixture based on its co<br>to acute toxicity at the upper three                          | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140<br>see GHS/CLP Table 3.1.2). The<br>mponents and do not represent<br>shold of category 4 for the cor<br>MOAEL Cutaneous<br>mg/kg bw/d | s mg/m3·4h Inhalat<br>t > 1230 l<br>t > 2050 l<br>s mg/m3·4h Inhalat<br>A mg/m3·4h Inhalat<br>> *><br>hese values are designed<br>ent test results.<br>rresponding exposure rout<br>NOAEC Inhalat |
|        | Dose and lethal concerned for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati         (-) - The components the are ignored.         - No observed adverse         1,2-benzisothiazol-3(3         - Lowest observed adverse         Not available | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>acute toxicity corresponding<br>on of the ATE for classification<br>and are assumed to have not<br>be effect level<br>2H)-one<br>dverse effect level | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>ATE<br>mg/kg bw Ora<br>490<br>74,9<br>*567<br>ng to the classification category (<br>ation of a mixture based on its co<br>to acute toxicity at the upper three<br>NOAEL Ora<br>mg/kg bw/d          | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140<br>see GHS/CLP Table 3.1.2). The<br>mponents and do not represe<br>shold of category 4 for the con<br>MOAEL Cutaneous<br>mg/kg bw/d   | s mg/m3·4h Inhalat<br>t > 1230 f<br>t > 2050 f<br>s mg/m3·4h Inhalat<br>A mg/m3·4h Inhalat<br>bese values are designed<br>ont test results.<br>rresponding exposure rout<br>NOAEC Inhalat         |
|        | Dose and lethal concerned for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati         (-) - The components the are ignored.         - No observed adverse         1,2-benzisothiazol-3(3         - Lowest observed adverse         Not available | nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>xicity (ATE)<br>nts:<br>2H)-one<br>hloro-2-methyl-2H-<br>C 247-500-7] and 2-<br>3-one [EC 220-239-6]<br>2H)-one<br>acute toxicity corresponding<br>on of the ATE for classification<br>and are assumed to have not<br>be effect level<br>2H)-one<br>dverse effect level | DL50 (OECD401)<br>mg/kg bw Ora<br>490 Ra<br>74,9 Ra<br>1020 Ra<br>1020 Ra<br>MTE<br>mg/kg bw Ora<br>490<br>74,9<br>*567<br>ng to the classification category (<br>ation of a mixture based on its co<br>to acute toxicity at the upper three<br>NOAEL Ora<br>mg/kg bw/d<br>69 Ra | DL50 (OECD402<br>mg/kg bw Cutaneous<br>> 2000 Ra<br>140 Ra<br>> 2000 Ra<br>ATE<br>mg/kg bw Cutaneous<br>140<br>see GHS/CLP Table 3.1.2). The<br>mponents and do not represe<br>shold of category 4 for the con<br>MOAEL Cutaneous<br>mg/kg bw/d   | s mg/m3·4h Inhalat<br>t<br>t > 1230 F<br>s 2050 F<br>s mg/m3·4h Inhalat<br>o *><br>hese values are designed<br>ent test results.<br>rresponding exposure rout<br>s NOAEC Inhalat<br>mg/           |



DUEPOL ACQUA SUELOS SATINADO

s Code : 1656

| Version: 3                   | Revision: 11/03/2024 | Previ | ious revision: 23/12/2022   | Date of printing: | 11/03/2024          |
|------------------------------|----------------------|-------|---|-------------------|---------------------|
| Skin:<br>Not classified      | ATE > 5000 mg/kg bw  |       | Not classified as a product wi<br>in contact with skin (based on<br>the classification criteria are r | available data,   |                     |
| Eyes:<br>Not classified      | Not available.       |       | Not classified as a product wi<br>by eye contact (lack of data).                                      |                   | GHS/CLP<br>1.2.5.   |
| Ingestion:<br>Not classified | ATE > 5000 mg/kg bw  |       | Not classified as a product wi<br>if swallowed (based on availa<br>classification criteria are not r  | ble data, the     | GHS/CLP<br>3.1.3.6. |

GHS/CLP 3.1.3.6: Classification of mixtures based on ingredients of the mixture (additivity formula).

## CORROSION / IRRITATION / SENSITISATION :

| Danger class   | Target organs | Cat. | Main effects, acute and/or delayed  | Criteria                       |
|--|---------------|------|---|--------------------------------|
| <ul> <li>Respiratory corrosion/irritation:<br/>Not classified</li> </ul> | -             | -    | Not classified as a product corrosive or<br>irritant by inhalation (based on available data<br>the classification criteria are not met).            | GHS/CLP<br>,1.2.6.<br>3.8.3.4. |
| - Skin corrosion/irritation:<br>Not classified                           | -             | -    | Not classified as a product corrosive or<br>irritant in contact with skin (based on<br>available data, the classification criteria are<br>not met). | GHS/CLP<br>3.2.3.3.            |
| - Serious eye damage/irritation:<br>Not classified                       | -             | -    | Not classified as a product corrosive or<br>irritant in contact with eyes (based on<br>available data, the classification criteria are<br>not met). | GHS/CLP<br>3.3.3.3.            |
| <ul> <li>Respiratory sensitisation:<br/>Not classified</li> </ul>        | -             | -    | Not classified as a product sensitising by<br>inhalation (based on available data, the<br>classification criteria are not met).                     | GHS/CLP<br>3.4.3.3.            |
| - Skin sensitisation:<br>Not classified                                  | -             | -    | Not classified as a product sensitising by skin<br>contact (based on available data, the<br>classification criteria are not met).                   | GHS/CLP<br>3.4.3.3.            |

GHS/CLP 3.2.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.3.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.4.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

## - ASPIRATION HAZARD:

| Danger class                           | Target organs | Cat. | Main effects, acute and/or delayed | Criteria             |
|--|---------------|------|------------------------------------|----------------------|
| - Aspiration hazard:<br>Not classified | -             |      |                                    | GHS/CLP<br>3.10.3.3. |

GHS/CLP 3.10.3.3: Classification of the mixture when data are available for all components or only for some components.

<u>SPECIFIC TARGET ORGANS TOXICITY (STOT): Single exposure (SE) and/or Repeated exposure (RE):</u> Not classified as a dangerous product for target organs.

GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

CMR EFFECTS:

- Carcinogenic effects:

It is not considered as a carcinogenic product.

- Genotoxicity:

It is not considered as a mutagenic product.

Toxicity for reproduction:

Does not harm fertility.Does not harm the unborn child.

- Effects via lactation:

Not classified as a hazardous product for children breast-fed.

DELAYED AND IMMEDIATE EFFECTS AS WELL AS CHRONIC EFFECTS FROM SHORT AND LONG-TERM EXPOSURE: Routes of exposure Not available. - Short-term exposure: # Causes skin irritation. Causes serious eye damage. May cause respiratory irritation. May cause drowsiness or dizziness. - Long-term or repeated exposure: Not available.

|  | ,  |  | lation (EU) No. 2020/878  |   | (Language:E  |
|--|--|--|---|---|--|
|  | DUEPOL AC<br>Code : 1656   | QUA SUE  | LOS SATINADO  |   |  |
| ersion: 3 Rev  | vision: 11/03/   | 2024   | Previou   | s revision: 23/12/2022  | Date of printing: 11/03/202  |
| INTERACTIVE EFFE   | ECTS:  |  |   |   |  |
| Not available.   |  |  |   |   |  |
| INFORMATION ABC  | <u>) UT TOXICO</u>   |  | S, METABOLISM AND DISTRIBUTI  | <u>ON:</u>  |  |
| - Dermal absorption  | •  |  |   |   |  |
| Not available.<br>- Basic toxicokinetic  | ·c.  |  |   |   |  |
| Not available.   | <u>o.</u>  |  |   |   |  |
|  |  |  |   |   |  |
| ADDITIONAL INFOR<br>Not available.   | <u>KIVIATION:</u>  |  |   |   |  |
| 1.2 INFORMATION ON   | OTHER HAZ  | ARDS:  |   |   |  |
| Endocrine disrupting   |  |  |   |   |  |
| This product does not<br>Other information:  | contain substa   | nces with  | endocrine disrupting properties identifie   | ed or under evaluation.   |  |
| No additional informati  | ion available.   |  |   |   |  |
| ECTION 12: ECOLOGICAL INF  | ORMATION   |  |   |   |  |
| # No experimental e  | cotoxicologica   | l data on  | the preparation as such is available  | e. The ecotoxicological cla   | assification for these   |
| mixture has been can<br>(CLP).   | rried out by us  | sing the c   | onventional calculation method of th  | ne Regulation (EU) No. 12   | 272/2008~2022/692  |
|  |  |  |   |   |  |
| - Acute toxicity in aqu  |  | nent   | CL50 (OECD 203)   | CE50 (OECD 202)   | CE50 (OECD 20  |
| for individual ingredie  |  |  | mg/I·96hours  | mg/l·48hours  | mg/l·72hou   |
| 1,2-benzisothiazol-3(<br>Reaction mass of 5-c  | · /  |  | 2.2 - Fishes<br>0.19 - Fishes   | 2.9 - Daphniae<br>0.16 - Daphniae   | 0.11 - Alga<br>0.037 - Alga  |
| isothiazolin-3-one [E  | C 247-500-7]   | and 2-   |   | 0.10 - Daprinae   | 0.037 - Alg  |
| methyl-2H-isothiazol   | -3-one [EC 22  | 0-239-6]   |   |   |  |
| (3:1)<br>1,2-benzisothiazol-3(   | (2H)-one   |  | 1.2 - Fishes  | 0.85 - Daphniae   | 0.37 - Alg   |
| 1,2-00121301110201-0(  |  |  | 1.2 - 1 151105  | 0.00 - Daprinac   | 0.07 - 749   |
| - No observed effect   | concentration  | 1  | NOEC (OECD 210)<br>mg/l · 28 days   | NOEC (OECD 211)<br>mg/l · 21 days   | NOEC (OECD 20<br>mg/l · 72 hou   |
| 1,2-benzisothiazol-3(  | (2H)-one   |  | mg/r 20 days  | ing/i 21 days   | 0.04 - Alga  |
| Reaction mass of 5-c   |  |  | 0.02 - Fishes   | 0.011 - Daphniae  | 0.004 - Alga   |
| isothiazolin-3-one [E0<br>methyl-2H-isothiazol-  |  |  |   |   |  |
| (3:1)  |  | .0 200 0]  |   |   |  |
|  |  |  | · · ·   |   |  |
| - Lowest observed en<br>Not available  | ffect concentra  | ation  |   |   |  |
| ASSESSMENT OF A  |  | XICITY:  |   |   |  |
|  |  | Cat.   | Main hazards to the aquatic environme   | ent   | Criteria   |
| Aquatic toxicity   |  |  |   |   |  |
|  |  |  | Not classified as a bazardous product   | with acute toxicity to aquatic  |  |
| Aquatic toxicity<br>- Acute aquatic toxicit<br>Not classified  |  |  | Not classified as a hazardous product<br>(based on available data, the classifica   |   | c life GHS/CLP<br>4.1.3.5.5.3.   |
| - Acute aquatic toxicit  | ty:  | -  | (based on available data, the classifica<br>Not classified as a dangerous product   | ation criteria are not met).<br>with chronic toxicity to aqua   | 4.1.3.5.5.3.<br>atic life GHS/CLP  |
| - Acute aquatic toxicit<br>Not classified  | ty:  | -  | (based on available data, the classifica  | ation criteria are not met).<br>with chronic toxicity to aqua   | 4.1.3.5.5.3.<br>atic life GHS/CLP  |
| <ul> <li>Acute aquatic toxicit</li> <li>Not classified</li> <li>Chronic aquatic toxi</li> </ul>  | ty:<br>icity:  | -  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).  | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classificatior  | 4.1.3.5.5.3.<br>atic life GHS/CLP  |
| <ul> <li>Acute aquatic toxicit</li> <li>Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class</li> </ul>  | ty:<br>icity:<br>sification of a m   | -<br>ixture for a  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of  | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.  | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>n criteria 4.1.3.5.5.4.   |
| <ul> <li>Acute aquatic toxicit<br/>Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class<br/>CLP 4.1.3.5.5.4: Class</li> </ul>  | ty:<br>icity:<br>sification of a m<br>sification of a m  | -<br>ixture for a<br>ixture for c  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).  | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.  | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>n criteria 4.1.3.5.5.4.   |
| Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class     CLP 4.1.3.5.5.4: Class 2.2 PERSISTENCE ANE  | ty:<br>icity:<br>sification of a m<br>sification of a m  | -<br>ixture for a<br>ixture for c  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of  | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.  | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>n criteria 4.1.3.5.5.4.   |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     Biodegradability:  | ty:<br>icity:<br>sification of a m<br>sification of a m  | -<br>ixture for a<br>ixture for c  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of  | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.  | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>n criteria 4.1.3.5.5.4.   |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     - Biodegradability:<br>Not available.<br>Aerobic biodegradati  | ty:<br>icity:<br>sification of a m<br>sification of a m<br>D DEGRADAE  | -<br>ixture for a<br>ixture for c  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO                                       | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>n criteria 4.1.3.5.5.4.   |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     - Biodegradability:<br>Not available.<br>Aerobic biodegradati<br>for individual ingredie   | ty:<br>icity:<br>sification of a m<br>sification of a m<br>D DEGRADAE<br>ion<br>ents   | -<br>ixture for a<br>ixture for c  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com   | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid                                |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     DERSISTENCE AND     - Biodegradability:<br>Not available.     Aerobic biodegradati<br>for individual ingredie<br>1,2-benzisothiazol-3(  | ty:<br>icity:<br>sification of a m<br>sification of a m<br>D DEGRADAE<br>ion<br>ents<br>(2H)-one   | -<br>ixture for a<br>ixture for o  | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO<br>5 days 14 days 28 days<br>         | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid                                |
| <ul> <li>Acute aquatic toxicit<br/>Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class<br/>CLP 4.1.3.5.5.4: Class</li> <li>2.2 PERSISTENCE AND<br/>- Biodegradability:<br/>Not available.</li> <li>Aerobic biodegradati<br/>for individual ingredice</li> </ul>   | ty:<br>icity:<br>sification of a m<br>sification of a m<br>D DEGRADAE<br>D DEGRADAE<br>(2H)-one<br>chloro-2-methy  | -<br>ixture for a<br>ixture for o<br>BILITY:<br>yl-2H-                               | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO                                       | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid                                |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class<br>CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE ANE     - Biodegradability:<br>Not available.<br>Aerobic biodegradati<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-co<br>isothiazolin-3-one [E0<br>methyl-2H-isothiazol-  | ty:<br>icity:<br>icity:<br>isification of a m<br>ification of a m<br>D DEGRADAE<br>D DEGRADAE<br>ion<br>ents<br>(2H)-one<br>chloro-2-meth<br>C 247-500-7]                      | -<br>ixture for a<br>ixture for o<br>BILITY:<br>yl-2H-<br>and 2-                     | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO<br>5 days 14 days 28 days<br>         | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid                                |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxic<br>CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class<br>CLP 4.1.3.5.5.4: Class<br>2.2 PERSISTENCE AND<br><u>- Biodegradability:</u><br>Not available.<br>Aerobic biodegradatii<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [Eo<br>methyl-2H-isothiazol-<br>(3:1)  | ty:<br>icity:<br>icity:<br>ification of a m<br>sification of a m<br>D DEGRADAE<br>D DEGRADAE<br>ion<br>ents<br>(2H)-one<br>chloro-2-methy<br>C 247-500-7]<br>-3-one [EC 22     | -<br>ixture for a<br>ixture for o<br>BILITY:<br>yl-2H-<br>and 2-                     | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO<br>5 days 14 days 28 days<br>         | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>ponents.<br>Biodegradabilid<br>Not ea<br>Not ea             |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxic<br>CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class<br>CLP 4.1.3.5.5.4: Class<br>2.2 PERSISTENCE ANE<br>- Biodegradability:<br>Not available.<br>Aerobic biodegradatil<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [E4<br>methyl-2H-isothiazol-3(<br>(3:1)<br>1,2-benzisothiazol-3(  | ty:<br>icity:<br>isification of a m<br>sification of a m<br>D DEGRADAE<br>D DEGRADAE<br>ion<br>ents<br>(2H)-one<br>chloro-2-methy<br>C 247-500-7]<br>-3-one [EC 22<br>(2H)-one | -<br>ixture for a<br>ixture for o<br><u>3ILITY:</u><br>yl-2H-<br>and 2-<br>20-239-6] | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO<br>5 days 14 days 28 days<br>55<br>55 | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid                                |
| Acute aquatic toxicit<br>Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class<br>CLP 4.1.3.5.5.4: Class<br>CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     Acrobic biodegradability:<br>Not available.<br>Aerobic biodegradatil<br>for individual ingredie<br>1,2-benzisothiazol-3(<br>Reaction mass of 5-c<br>isothiazolin-3-one [E0]<br>methyl-2H-isothiazol-3(<br>(3:1)<br>1,2-benzisothiazol-3( | ty:<br>icity:<br>isification of a m<br>sification of a m<br>D DEGRADAE<br>D DEGRADAE<br>ion<br>ents<br>(2H)-one<br>chloro-2-methy<br>C 247-500-7]<br>-3-one [EC 22<br>(2H)-one | -<br>ixture for a<br>ixture for o<br><u>3ILITY:</u><br>yl-2H-<br>and 2-<br>20-239-6] | (based on available data, the classifica<br>Not classified as a dangerous product<br>with long lasting effects (based on avai<br>are not met).<br>acute hazards, based on summation of<br>chronic (long term) hazards, based on s | ation criteria are not met).<br>with chronic toxicity to aqua<br>ilable data, the classification<br>classified components.<br>summation of classified com<br>%DBO/DQO<br>5 days 14 days 28 days<br>55<br>55 | 4.1.3.5.5.3.<br>atic life GHS/CLP<br>h criteria 4.1.3.5.5.4.<br>nponents.<br>Biodegradabilid<br>Not ea<br>Not ea |

| Photodegradability:<br>Not available.      Bioaccumulation     IogPow     BCF     Poi     Decommulation     IogPow     BCF     Poi     Decommulation     IogPow     IogPow     BCF     Poi     Decommulation     IogPow  | Printers     Code: 1956      Previous revision: 2012/2022     Date of printing: 1103/2024     Previous revision: 2012/2022     Date of printing: 1103/20     Previous revision: 2012/2022     Unikely, 1     Prevision: 2012/2023/2014/201     Unikely, 1     Prevision: 2012/2023/2014/201     Unikely, 1     Prevision: 2012/2013/2014/2014     Prevision: 2012/2014/2014     Prevision: 2012/2014/2014/2014/2014/2014/2014/2014/  | accorda | Y DATA SHEET (F<br>ance with Regulation (EC  | C) No. 1907/2006 a  | nd Regulation (   | EU) No. 2020/878   |   | (Language:E  |  |  |
|--|---|---------|--|---|---|--|---|--|--|--|
| Photodegradability:     Not available     Bioaccumulation     Bioaccumulatin     Bioaccumulation     Bioaccumulation     Bioaccumulation   | - Photodegradability:<br>Not available.       Not available.         12.3       BIOACCUMULATIVE POTENTIAL:<br>Not available.       IogPow       BIOACCUMULATIVE POTENTIAL:<br>Not available.         12.4       BIOACCUMULATIVE POTENTIAL:<br>Not available.       IogPow       BIOACCUMULATIVE POTENTIAL:<br>Not available.         12.5       BIOACCUMULATIVE POTENTIAL:<br>Not available.       IogPow       BIOACCUMULATIVE POTENTIAL:<br>Not available.         12.4       Motification-3-one [EC 247-500-7] and 2-<br>prestly-i241-isothiazol-3-one [EC 220-239-6]<br>(3:1)       I.2.5-enzisothiazol-3-one [EC 220-239-6]<br>(3:1)       Unlikely. I         12.4       Mot available       Iog Poc<br>Penzisothiazol-3-One [EC 247-500-7] and 2-<br>prestly-i241-isothiazol-3-One [EC 220-239-6]<br>(3:1)       Unlikely. I         12.4       Not available       Iog Poc<br>Penzisothiazol-3(2H)-one       0.97       Unlikely. I         Not available       IogPoc<br>Penzisothiazol-3(2H)-one       0.97       Unlikely. I         12.5       RESULTS OF PBT AND VPV8 ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT//PVB criteria.       Unlikely. I         12.6       ENDOCINE DISRUPTINES POPPETIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       O11FER ADVERSE EFFECTIS:<br>-0.20ne depletion potential:<br>Not available.<br>-Photochemical coone creation potential:<br>Not available.<br>-Photochemical coone creation potential:<br>Not available.<br>-Photochemical coone creation potential:<br>Not availabl   | К       | isaval   |   | UA SUELOS S/  | ATINADO  |   |  |  |  |
| Not available.           12.3         BIOACCUMULATIVE POTENTIAL:<br>Not available.           BIOACCUMULATIVE POTENTIAL:<br>Not available.         IogPow         BCF         Pol           Live         O.7         6.62 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H.         0.7         3.2 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H.         0.75         3.2 (calculated)         Unlikel           sothiazolin-3-one [EC 220-239-6]         (31)         1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           Mobility         Incertain to fill the provide t   | Not available.           [2:3]         BIGACCUMULATIVE POTENTIAL:<br>Not available.           [3:1]         Not available.           [1:2-benzisothiazol-3(2H)-one         0.7           [3:1]         Reaction mass of 5-chloro-2-methyl-2H-<br>sothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         0.75           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           [2:5]         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006:)         Des not contain substances with endocrine disrupting properties identified or under evaluation.           [2:6]         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006:)         Des not contain substances with endocrine disrupting properties identi   | ersior  | n: 3 Re  | evision: 11/03/20   | )24   | Prev   | ious revision: 23/12/2022   | Date of printing: 11/03/202                              |  |  |
| 12.3       BIOACCLIMULATIVE POTENTIAL:<br>Not available.         Bioaccumulation<br>for individual ingredients       logPow       BCF<br>LAQ         12-benzisothiza/3.2N=One       0.7       6.62 (calculated)       Unlikel<br>sothizazion-3-one [EC 247-500-7] and 2.         statisztim-3-one [EC 247-500-7] and 2.       0.75       3.2 (calculated)       Unlikel         sothizazion-3-one [EC 247-500-7] and 2.       0.64       3.2 (calculated)       Unlikel         12-benzisothiza/0-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility<br>for individual ingredients       log Poc       Constant of Henry<br>PamSmo 27C       Pol         12-benzisothiza/0-3(2H)-one       0.97       Vanikel       Unlikel         sothizabiliza/0-3(2H)-one       0.97       Vanikel       Unlikel         sothiza/oin-3-one [EC 247-500-7] and 2.       0.45       Unlikel         sothizabiliza-0-3(2H)-one       1.05       Unlikel         12-benzisothiza-0-3(2H)-one  | 12.3       BIOACCUMULATIVE POTENTIAL:<br>Not available.         Not available.       Bioaccumulation<br>individual ingredients       logPow       BCF       Poten         12.5enzisothiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikely, I         sothiazolin-3-one [EC 220-239-6]       3.2 (calculated)       Unlikely, I         31       12.5enzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         12.4       MOBILITY IN SOIL:<br>Not available       0.64       3.2 (calculated)       Unlikely, I         12.4       Not available       0.64       3.2 (calculated)       Unlikely, I         12.5       Reaction mass of 5-chloro-2-methyl-2H-<br>sothiazol-3(2H)-one       0.97       Poten       Poten         12.5       RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)       Does no contain substances that fulfil the PBT/VPB criteria.       ENDOCRINE DISRUETING PROPERTIES:<br>This product does not contain substances that fulfil the PBT/VPB criteria.       ENDOCRINE DISRUETING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       OTHER ADVERSE EFFECTS:<br>-0.20ne depletion potential:<br>Not available.       -0.20ne depletion potential:<br>Not available.   |         |  | <u>/:</u>   |   |  |   |  |  |  |
| Not available.           Bioaccumulation         logPow         BCF         Pol           L2-benzisofilizzol-3(2H)-one         0.7         6.62 (calculated)         Unlikel           Reaction mass of 5-choro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikel           3(1)         1_2-benzisofiliazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           MoBility         log Poc         Constant of Henry<br>Pamämo 27C         Pol           Mot available         0.97         Unlikel         Unlikel           Mobility in stoluzol-3(2H)-one         0.97         Unlikel           Reaction mass of 5-choro-2-methyl-2H-<br>isothiazolin-3one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-238-6]<br>(3:1)         Unlikel         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel         Unlikel           Resection mass of 5-choro-2-methyl-2H-<br>isothiazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05<   | Not available.           Bioaccumulation<br>for individual ingredients         logPow         BCF         Poten           1.2-benzisofhiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H-<br>sothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3-one [EC 220-239-6]         0.64         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           MoBility<br>for individual ingredients         log Poc<br>Por matively Pam3inol 20°C         Poten           1.2-benzisothiazol-3(2H)-one         0.97         Constant of Henry<br>Pam3inol 20°C         Poten           1.2-benzisothiazol-3(2H)-one         0.97         Unlikely, I         unlikely, I           1.2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           1.3:1         1.2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           1.2:6         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)         Does not contain substances with endocrine disrupting properties identified or under evaluation.           1:7         OTHER ADVERSE EFFECTS:         .         Ozone depletion potential:<br>Not available.           1:7<   | 2.3     |  | F POTENTIAL :   |   |  |   |  |  |  |
| Ici         Ici         Ici           12-benzisothiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           (3:1)         1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           Not available         0.97         Pol         Pol           Not available         0.97         Unlikel         Not available           Not available         0.97         Unlikel         Not available         Unlikel           Reaction mass of 5-chloro-2-methyl-2H-<br>sothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         1.05         Unlikel           12-benzisothiazol-3(2H)-one         1.05         Unlikel         Unlikel           13-1         Reaction mass of 5-chloro-2-methyl-2H-<br>sothiazol-3(2H)-one         1.05         Unlikel           12-6         RESULTS OF PBT AND VPVB ASESEMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         <  | for individual ingredients         Use           1.2-benzisothiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikely, I           Reaction mass of 5-chlore-2-methyl-2H-<br>isothiazoli-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         0.75         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           Not available         Not available         Not available         Not available           Mobility         log Pod         Constant of Henry<br>Pam3tm0 20°C         Poten<br>Pam3tm0 20°C         Poten<br>Pam3tm0 20°C         Poten<br>Pam3tm0 20°C         Unlikely, I           I.2-benzisothiazol-3(2H)-one         0,97         Unlikely, I         Unlikely, I         Sothiazoli-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         1,05         Unlikely, I           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05 </td <td>12.0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>  | 12.0    |  |   |   |  |   |  |  |  |
| 12.2benzisothiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-       0.75       3.2 (calculated)       Unlikel         sothiazol-3-QH)-one       0.64       3.2 (calculated)       Unlikel         (3:1)       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       for individual ingredients       10g Poc       Constant of Henry       Pol         Mobility       for individual ingredients       0.97       Unlikel       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-       0.45       Unlikel       Unlikel         sothiazol-3(2H)-one       1.05       Unlikel       Unlikel         12-benzisothiazol-3(2H)-one       1.05       Unlikel       Unlikel         12-benzisothiazol-3(2H)-one       1.05       Unlikel         12.6       ENDCCRNE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.       10.7         12.7       OTHER ADVERSE EFFECTS:       - Ozone depletion potential:       Not available.       - Potochemical azone creation potential:         Not available.       - Potochet  | 12-Henzisofhiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H.       0.75       3.2 (calculated)       Unlikely, I         softiazoln-3-one [EC 220-239-6]       0.75       3.2 (calculated)       Unlikely, I         (3:1)       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         Not available       0       0.64       3.2 (calculated)       Unlikely, I         Not available       0       90       Poten       Par.Mon.200C       Poten         Not available       0.97       Constant of Henry       Poten       Poten       Par.Mon.200C       Unlikely, I         12-benzisothiazol-3(2H)-one       0.97       Unlikely, I       Unlikely, I       Unlikely, I       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I       Unlikely, I       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I  |         |  | -   |   | logPow   |   |  |  |  |
| Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikel           (3:1)         1,2-benzisothiazol-3-one [EC 220-239-6]         0.64         3.2 (calculated)         Unlikel           Not available         0.64         3.2 (calculated)         Unlikel           MOBILITY IN SOIL:<br>Not available         0.64         3.2 (calculated)         Unlikel           Mobility<br>for individual ingredients         0.97         Perm3mol 29°C         Poil           I_2-benzisothiazol-3(2H)-one         0.97         Unlikel         Unlikel           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3.1)         1.05         Unlikel           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006):<br>Does not contain substances with endocrine disrupting properties identified or under evaluation.         1.05           12.6         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         1.07           12.7         OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential;<br>Not available:<br>- Earthi dobal warming potential;<br>Not available:<br>- Earth idoba  | Reaction mass of 5-chloro-2-methyl-2H-<br>bothizzolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothizzoli-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikely, I           (3:1)         12-benzisothizzol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           12.4         MOBILITY IN SOIL.<br>Not available         0.64         3.2 (calculated)         Unlikely, I           12.4         MOBILITY IN SOIL.<br>Not available         0.97         Constant of Henry<br>Pa-m3/mol 20°C         Poten           12.4         MOBILITY IN SOIL.<br>Not available         0.97         Unlikely, I         Unlikely, I           12-benzisothizazol-3(2H)-one         0.97         Unlikely, I         Unlikely, I           12-benzisothizazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothizazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothizazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothizazol-3-One [EC 220-8]         Unlikely, I           12-5         RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)<br>Does not contain substances that fulfi the PBT/VPVB criteria.         DocCNINE DISRUPTING PMCPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.  |         | <b>Ç</b>   |   |   | 0.7  |   | 5  |  |  |
| isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]       Initiazolin-3-one [EC 220-239-6]         [1,2-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       Iog Poc       Constant of Henry       Pol         Not available       0.97       Para3mot 20°C       Unlikel         Iz-benzisothiazol-3(2H)-one       0.97       Unlikel       Iog Poc       Status 20°C         1,2-benzisothiazol-3(2H)-one       0.97       Unlikel       Ionizolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one       1,05       Unlikel         1,2-benzisothiazol-3(2H)-one       1,05       Unlikel       Ionizolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one       1,05       Unlikel         12.5       RESULTS OF PET AND VPVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.       .         12.7       OTHER ADVERSE EFFECTS:       -       -       -         .       -Drotochemical ozone creation potential:       Not available.       .         .       -Pholochemical ozone creation potential:       Not available.       .         . <td>isothiazolin3-one [EC 247-500-7] and 2-<br/>methyl-2H-isothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL;<br/>Not available       Iog Pod<br/>Poten       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL;<br/>Not available       Iog Pod<br/>Poten       Constant of Henry       Poten         [3.1]       I_2-benzisothiazol-3(2H)-one       0.97       Unlikely, I         [3.2]       Reaction mass of 5-chloro-2-methyl-2H-<br/>isothiazolin3-one [EC 247-500-7] and 2-<br/>methyl-2H-isothiazol-3(2H)-one       0.97       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.2]       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.6]       ENDOCRINE DISRUPTING PROPERTIES:<br/>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.7]       OTHER ADVERSE EFFECTS:<br/>- Ozone depletion potential:<br/>Not available.       -Description       101         [3.1]       MASET TRRATMENT METHODS: Directive 2008/98/EC-Regulation (</td> <td></td> <td></td> <td>· /</td> <td>211</td> <td></td> <td></td> <td>,</td> | isothiazolin3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL;<br>Not available       Iog Pod<br>Poten       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL;<br>Not available       Iog Pod<br>Poten       Constant of Henry       Poten         [3.1]       I_2-benzisothiazol-3(2H)-one       0.97       Unlikely, I         [3.2]       Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one       0.97       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.2]       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.6]       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.7]       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.       -Description       101         [3.1]       MASET TRRATMENT METHODS: Directive 2008/98/EC-Regulation (   |         |  | · /   | 211   |  |   | ,  |  |  |
| 12.4       MOBILITY IN SOIL:<br>Not available       Iog Pod<br>Constant of Henry<br>Parm3/mol 20°C       Pot<br>Parm3/mol 20°C         Mobility<br>for individual ingredients       Iog Pod<br>Constant of Henry<br>Parm3/mol 20°C       Pot         Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazol-3-(2H)-one<br>Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT/vPvB criteria.       Unlikel         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       IOTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.         Photochemical ozone creation potential:<br>Not available.       Earth global warming potential:<br>Not available.       Batochemical ozone creation potential:<br>Not available.         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: And packaging should be disposed in accordance with current local   | 12.4       MOBILITY IN SOIL:<br>Not available       Not available         MOBILITY IN SOIL:<br>Not available       Iog Poc       Constant of Henry<br>Pam3/mol 20°C       Poten         1,2-benzisothiazol-3(2H)-one       0,97       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazoli-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)       Unlikely, I         1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT/VPB or iteria.       Iunlikely, I         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Iunlikely, I         12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.       - Denochemical ozone creation potential:<br>Not available.       - Earth global warming potential;<br>Not available.         13.1       Take all necessary measures to prevent the production of waste whenever possible, Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controis and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/   |         | isothiazolin-3-one [E<br>methyl-2H-isothiazo   | EC 247-500-7] ar  | nd 2-   | 0.75   | 3.2 (Calculate  | ea) Onlikely, lo   |  |  |
| Not available           Mobility         Iog Poc         Constant of Henry<br>Pa:m3/mol 20°C         Pol           1,2-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3(2H)-one         1,05         Unlikel           12-5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;)<br>Does not contain substances that fulfil the PBT/vPvB criteria.         100         100           12-6         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         112.7         OTHER ADVERSE EFFECTS:<br>Ozone depletion potential:<br>Not available.        Denotencial coone creation potential:<br>Not available.        Photochemical ozone creation potential:<br>Not available.         Not available.           13.1         WASTE TREATMENT METHODS:Directive 2008/98/ECRegulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers  | Not available         Iog Poc         Constant of Henry<br>Parm3/mol 20°C         Poten           1,2-benzisothiazol-3(2H)-one         0,97         Unlikely, 1           Reaction mass of 5-chioro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)         Unlikely, 1           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, 1           22.6         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         Does not contain substances that fulfil the PBT/vPvB criteria.           12.6         ENDOCRINE DISRUPTING PROPERTIES:         This product does not contain substances with endocrine disrupting properties identified or under evaluation.         10           12.7         OZnene depletion potential:<br>Not available.         -         -           - Photochemical zone creation potential:<br>Not available.         -         Not available.         -           - SCONN 13: DISPOSAL CONSIDERATIONS         If the antherose matherose mathero   |         | 1,2-benzisothiazol-3   | B(2H)-one   |   | 0.64   | 3.2 (calculate  | ed) Unlikely, lo   |  |  |
| Mobility<br>for individual ingredients         log Pod<br>for individual ingredients         Pod<br>Parm3/mol 20°C           12-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 239-6]<br>(3:1)         0,45         Unlikel           12-5         RESULTS OF PBT AND VPVB ASSESMENT.(Annex XIII of Regulation (EC) no. 1907/2006.)         Unlikel           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7           OTHER ADVERSE EFFECTS:<br>-Ozone depletion potential:<br>Not available.         -Ozone depletion potential:<br>Not available.         Not available.           ECTION 13: DISPOSAL CONSIDERATIONS         Usate should be product does for revaluation of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers.Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU.         # Emptied containers and packaging should be disposed in accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8. <t< td=""><td>Mobility         log Pod<br/>for individual ingredients         log Pod<br/>for individual ingredients         Poten<br/>Para3/mol 20°C           1, 2-benzisothiazol-3(2H)-one         0,97         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H-<br/>isothiazolin-3-one [EC 247-500-7] and 2-<br/>methyl-2H-isothiazol-3-one [EC 220-239-6]<br/>(3:1)         Unlikely, I         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES:<br/>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         Indix 201-202-202-202-202-202-202-202-202-202-</td><td>2.4</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>   | Mobility         log Pod<br>for individual ingredients         log Pod<br>for individual ingredients         Poten<br>Para3/mol 20°C           1, 2-benzisothiazol-3(2H)-one         0,97         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)         Unlikely, I         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         Indix 201-202-202-202-202-202-202-202-202-202-  | 2.4     |  |   |   |  |   |  |  |  |
| for individual ingredients         Parm3/mol 20°C           1,2-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chtoro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)         Unlikel         Unlikel           1,2-benzisothiazol-3(2H)-one         1,05         Unlikel           1,2-benzisothiazol-3(2H)-one         1,05         Unlikel           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         Does not contain substances that fulfil the PBT/VPVB criteria.           12.6         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         .           2.7         OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.         .         .           2.7         OTHER ADVERSE EFFECTS:<br>- Photochemical ozone creation potential:<br>Not available.         .         .           3.1         WASTE TREATMENT METHODS:Directive 2008/98/EC=Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and protection measures, see section 8.           LER code         Description         Type of waste   | for individual ingredients         Parm3/mol 20°C           1,2-benzisothiazol-3(2H)-one         0,97           Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT/vPvB criteria.         Unlikely, I           12.6         ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.            12.7         OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.             - Earth global warming potential:<br>Not available.              13.1         WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging ab  |         |  |   |   |  |   |  |  |  |
| 1,2-benzisothiazol-3(2H)-one       0,97       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-(2H)-one       0,45       Unlikel         1,2-benzisothiazol-3-(2H)-one       1,05       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT/vPvB criteria.       Unlikel         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Unlikel         12.7       OTHER ADVERSE EFFECTS:<br>-Ozone depletion potential:<br>Not available.       -Photochemical ozone creation potential:<br>Not available.       Not available.         2.5       EETH global warming potential:<br>Not available.       Not available.       -Earth global warming potential:<br>Not available.         13.1       WASTE TREATMENT METHODS.Directive 2008/98/EC-Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local an national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: Directive 94/62/EC-2015/720/EU. Decision 2000/532/EC-2014/955   | 12-benzisothiazol-3(2H)-one       0,97       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H-isothiazoln-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 220-239-6]       Unlikely, I         (3:1)       1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)       Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:      ocone depletion potential:         Not available.      Photochemical ozone creation potential:         Not available.      Photochemical ozone creation potential:         Not available.      Disposal CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014:         Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste <tr< td=""><td></td><td></td><td>ients</td><td></td><td>log Poc</td><td></td><td></td></tr<>  |         |  | ients   |   | log Poc  |   |  |  |  |
| Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)       Unlikel         12-5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PT/VPVB criteria.       Unlikel         12-6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Unlikel         12-7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.       - Photochemical ozone creation potential:<br>Not available.         13-1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste<br>Non-hazardous         Disposal of empty containers:Directive 94/62/EC-2015/720/EU. Decision 2000/532/EC-2014/955/EU:<br># Emptied containers and packaging abould be disposed in accordance with currently local and national regulations. The classification<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC-2014/955/EU:<br># Emptied cont  | Reaction mass of 5-chloro-2-methyl-2H-<br>isothiazolin-3-one [EC 247-500-7] and 2-<br>methyl-2H-isothiazol-3-one [EC 220-239-6]<br>(3:1)       Unlikely, I         Iter 1, 2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         Iter 2, 200, 200, 200, 200, 200, 200, 200,   |         |  |   |   | 0.97   |   | Unlikelv. lo   |  |  |
| 1,2-benzisothiazol-3(2H)-one       1,05       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006:)<br>Does not contain substances that fulfil the PBT/VPVB criteria.       12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.       12.7         0THER ADVERSE EFFECTS:<br>Ozone depletion potential:<br>Not available.<br>Earth global warming potential:<br>Not available.      Photochemical ozone creation potential:<br>Not available.      Earth global warming potential:<br>Not available.         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification -<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging adopt the same measures as for the product in itself.<br>Procedures for neut   | 1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, 1         12.5       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)<br>Does not contain substances that fulfil the PBT/VPvB criteria.       12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.       -         13.1       WASTE TREATMENT METHODSS       13.1         WASTE TREATMENT METHODSS       Indication of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste<br>Non-hazardous         Disposal of empty containers:Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. For exposure controls and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 0 1 of Decision 2000/532/EC-2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The   |         | Reaction mass of 5-<br>isothiazolin-3-one [E<br>methyl-2H-isothiazo  | -chloro-2-methyl-<br>EC 247-500-7] ar   | nd 2-   |  |   | Unlikely, lo   |  |  |
| 12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;)<br>Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>-Ozone depletion potential:<br>Not available.<br>-Enth global warming potential:<br>Not available.<br>-Earth global warming potential:<br>Not available.<br>-Earth global warming potential:<br>Not available.         2.1       TAKE TREATMENT METHODS: Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste<br>Non-hazardous         Disposal of empty containers.Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   | 12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;)<br>Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES;<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS;<br>- Ozone depletion potential;<br>Not available.         - Photochemical ozone creation potential;<br>Not available.       - Earth global warming potential;<br>Not available.         - ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS: Directive 2008/98/EC-Regulation (EU) no. 1357/2014;<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste<br>Non-hazardous         Disposal of empty containers.Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU;<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying   |         |  | 3(2H)-one   |   | 1.05   |   | Unlikely, la   |  |  |
| Does not contain substances that fulfil the PBT/vPvB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.<br>- Photochemical ozone creation potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emplied containers and packaging should be disposed in accordance with currently local and national regulations. The classification<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>containinated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | Does not contain substances that fulfil the PBT/vPvB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:<br>This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>Ozone depletion potential:<br>Not available.<br>Photochemical ozone creation potential:<br>Not available.<br>Earth global warming potential:<br>Not available.         CCTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS.Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging . Adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product;   | 2.5     |  |   | SESMENT: (Ar  |  | ) no. 1907/2006:)   | <b>,</b>   |  |  |
| This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.<br>- Photochemical ozone creation potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.<br>ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.<br>LER code Description Type of waste<br>Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification in packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.         - Photochemical ozone creation potential:<br>Not available.       - Photochemical ozone creation potential:<br>Not available.         - Earth global warming potential:<br>Not available.       - Earth global warming potential:<br>Not available.         Section 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste<br>Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  |         | Does not contain sub   | stances that fulfil t   | he PBT/vPvB   | criteria.  |   |  |  |  |
| 12.7       OTHER ADVERSE EFFECTS:<br>- Ozone depletion potential:<br>Not available.<br>- Photochemical ozone creation potential:<br>Not available.<br>- Earth global warming potential:<br>Not available.         2.5       - Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | 12.7       OTHER ADVERSE EFFECTS:<br>-Ozone depletion potential:<br>Not available.<br>-Photochemical ozone creation potential:<br>Not available.<br>-Earth global warming potential:<br>Not available.<br>-Earth global warming potential:<br>Not available.<br>ECTION 13: DISPOSAL CONSIDERATIONS          13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.<br>LER code   | 2.6     |  |   |   |  |   |  |  |  |
| Ozone depletion potential:<br>Not available.     Photochemical ozone creation potential:<br>Not available.     Earth global warming potential:<br>Not available.     ECTION 13: DISPOSAL CONSIDERATIONS      WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.     LER code     Description     Type of waste     Non-hazardous     Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.     Procedures for neutralising or destroying the product:  | - Ozone depletion potential:<br>Not available.     - Photochemical ozone creation potential:<br>Not available.     - Earth global warming potential:<br>Non-hazardous point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.     - ER code  | 0.7     |  |   | es with endocr  | ine disrupting properties ident  | tified or under evaluation.   |  |  |  |
| Not available.       - Photochemical ozone creation potential:<br>Not available.         - Earth global warming potential:<br>Not available.       - Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification is packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | Not available.       - Photochemical ozone creation potential:<br>Not available.         - Earth global warming potential:<br>Not available.       - Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13:1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   | 2.7     |  |   |   |  |   |  |  |  |
| Not available.         - Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste         Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   | Not available.         - Earth global warming potential:<br>Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  |         |  | ioterniar.  |   |  |   |  |  |  |
| - Earth global warming potential:<br>Not available.   ECTION 13: DISPOSAL CONSIDERATIONS  13.1  WASTE TREATMENT METHODS: Directive 2008/98/EC~Regulation (EU) no. 1357/2014:  Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.  LER code Description Type of waste Non-hazardous Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification or packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:   | -Earth global warming potential:<br>Not available.   CTION 13: DISPOSAL CONSIDERATIONS  I3.1  VASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.  LER code Description Type of waste Non-hazardous Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   |         | - Photochemical oz   | one creation pote   | ential:   |  |   |  |  |  |
| Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   |         |  |   |   |  |   |  |  |  |
| ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:   | Image: Construct of the |         |  | <u>ing potential:</u>   |   |  |   |  |  |  |
| 13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:<br>Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl<br>Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose<br>accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste         Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of<br>packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their<br>classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With<br>contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | MASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:         Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  |         |  |   |   |  |   |  |  |  |
| Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl         Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:       # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  |         |  |   | Directive 0000  | 100/EC Desulation (EU) as  | 4257/2044   |  |  |  |
| Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations.The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations.The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:  | 13.1    | Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed i |   |   |  |   |  |  |  |
| Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:<br># Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  |         | LER code   | Desci   | ription   |  |   | Type of waste  |  |  |
| # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  |         |  |   |   |  |   | Non-hazardous  |  |  |
| # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  | # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.<br>Procedures for neutralising or destroying the product:  |         | Disposal of empty of   | ontainers:Directi   | ve 94/62/EC~  | -2015/720/EU. Decision 20  | 00/532/EC~2014/955/E  | U:   |  |  |
|  |   |         | # Emptied containers<br>packaging as hazard<br>classification, in acco<br>contaminated contain<br><u>Procedures for neur</u>   | and packaging sh<br>ous waste will dep<br>rdance with Chapt<br>ers and packaging<br>tralising or destro | nould be disposed<br>end on the deg<br>ter 15 01 of De<br>g, adopt the sa<br>bying the proc | sed in accordance with curren<br>gree of empting of the same, b<br>cision 2000/532/EC, and forw<br>me measures as for the produ<br>luct: | tly local and national regu<br>being the holder of the res<br>arding to the appropriate f | lations.The classification of idue responsible for their |  |  |
|  |   |         |  |   |   |  |   |  |  |  |
|  |   |         |  |   |   |  |   |  |  |  |

| accorda    | ance with Regulation (ÈC)               | No. 1907/2006 and Regulation (EU) No. 202       | 0/878  | (Language:E                |
|------------|---|---|--|----------------------------|
|            | isaval                                  | DUEPOL ACQUA SUELOS SATINADO                    |  |                            |
| $\square$  | pinturas                                | Code : 1656                                     |  |                            |
| ersion     | n: 3 Rev                                | l<br>rision: 11/03/2024                         | Previous revision: 23/12/2022                    | Date of printing: 11/03/20 |
| ECTION     | 14: TRANSPORT INFO                      | ORMATION  |  |                            |
| 14.1       | UN NUMBER OR ID                         |   |  |                            |
|            | Not applicable                          |   |  |                            |
| 14.2       | UN PROPER SHIPP                         | ING NAME:                                       |  |                            |
|            | Not applicable                          |   |  |                            |
| 14.3       | TRANSPORT HAZA                          | RD CLASS(ES):                                   |  |                            |
|            | Transport by road (A                    | DR 2023) and                                    |  |                            |
|            | Transport by rail (RII                  | <u>) 2023):</u>                                 |  |                            |
|            | No reglamented                          |   |  |                            |
|            | Transport by sea (IM                    | <u>DG 40-20):</u>                               |  |                            |
|            | No reglamented                          | Q (ATA 0004)                                    |  |                            |
|            | Transport by air (ICA                   | <u>O/IATA 2021):</u>                            |  |                            |
|            | No reglamented<br>Transport by inland w |   |  |                            |
|            | No reglamented                          | <u>raterways (ADN).</u>                         |  |                            |
| 14.4       | PACKING GROUP:                          |   |  |                            |
| <b>T.T</b> | No reglamented                          |   |  |                            |
| 4.5        | ENVIRONMENTAL F                         | AZARDS:   |  |                            |
|            | Not applicable (not clas                | ssified as hazardous for the environment).      |  |                            |
| 14.6       | SPECIAL PRECAUT                         | IONS FOR USER:                                  |  |                            |
|            | upright and secure.                     |   | case of accident or spill. Always transport in c | losed containers that are  |
| 4.7        | MARITIME TRANSP<br>Not applicable.      | ORT IN BULK ACCORDING TO IMO IN                 | <u>NSTRUMENTS:</u>                               |                            |
| CTION      | 15: REGULATORY INF                      | ORMATION  |  |                            |
| 5.1        | SAFETY, HEALTH A                        | ND ENVIRONMENTAL REGULATION                     | S/LEGISLATION SPECIFIC FOR THE S                 | UBSTANCE OR MIXTUR         |
|            | The regulations applica                 | able to this product generally are listed thro  | ughout this Safety Data Sheet.                   |                            |
|            |   | facture, placing on market and use:             |  |                            |
|            | See section 1.2                         |   |  |                            |
|            | Tactile warning of da                   |   |  |                            |
|            |   | ssification criteria are not met).              |  |                            |
|            | Child safety protectio                  | <u>m:</u><br>ssification criteria are not met). |  |                            |
|            | VOC information on t                    |   |  |                            |
|            |   |   | nit value 2004/42/EC-IIA cat. j) Two-pack perl   | ormance coating water-     |
|            | borne. is VOC max. 14                   |   | ······································           | <b>3</b> ,                 |
|            | OTHER REGULATIC                         | <u>DNS:</u>                                     |  |                            |
|            | Not available.                          |   |  |                            |
|            |   | herent in major accidents (Seveso III):         |  |                            |
|            | See section 7.2                         |   |  |                            |
|            | Other local legislation                 |   |  |                            |
| 5.0        | CHEMICAL SAFETY                         | rify the possible existence of local regulation | ons applicable to the chemical.                  |                            |
| 5.2        |   | essment has not been carried out for this mi    | ivture   |                            |
|            | A chemical salety asse                  |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |
|            |   |   |  |                            |

| $\prec$                       | <b>isava</b>  | Code : 1656   |   |  |  |
|-------------------------------|---|---|---|--|--|
| rsion                         | n: 3 Rev  | ision: 11/03/2024   | Previous revision: 2  | 3/12/2022  | Date of printing: 11/03/202  |
| TION                          | 16 : OTHER INFORMA  | TION  |   |  |  |
| .1                            |   | SES AND NOTES REFERENCE   |   |  |  |
|                               | H301 Toxic if swallowed<br>H315 Causes skin irritat<br>toxic to aquatic life. H4:<br><u>Notes related to the id</u><br>Note B : Some substan<br>these solutions require<br>have a general designat<br>solution on the label. U<br><u>EVALUATION OF TH</u><br>See sections 9.1, 11.1   |   | Fatal in contact with skin. H314 Causes<br>in reaction. H318 Causes serious eye<br>lasting effects. EUH071 Corrosive to<br><u>elling of the substances or mixture</u><br>in the market in aqueous solutions at<br>ince the hazards vary at different cor<br>%'. In this case the supplier must<br>that the percentage concentration is<br><u>GER OF MIXTURES:</u> | es severe skin<br>e damage. H33<br>the respiratory<br>es:<br>various concer<br>ncentrations. In<br>state the perce | 0 Fatal if inhaled. H400 Ver<br>y tract.<br>htrations and, therefore,<br>h Part 3 entries with Note B<br>entage concentration of the |
|                               | It is recommended for a   | RAINING APPROPRIATE FOR W<br>III staff that will handle this product to<br>and interpretation of Safety Data She  | carry out a basic training in occupati  |  | prevention, in order to  |
|                               |   | REFERENCES AND SOURCES F  |   |  |  |
|                               |   | Agency: ECHA, http://echa.europa.e∟<br>Inion Law, http://eur-lex.europa.eu/<br>s, (AGCIH, 2021).  | 1/  |  |  |
|                               | · European agreement  | on the international carriage of dange<br>Dangerous Goods Code IMDG inclu   |   |  |  |
|                               |   | d acronyms that can be used (but no   | t necessarily used) in this Safety Dat  | a Sheet:   |  |
|                               | <ul> <li>EINECS: European In</li> <li>ELINCS: European Li</li> <li>CAS: Chemical Abstra</li> <li>UVCB: Substances of</li> <li>SVHC: Substances of</li> <li>PBT: Persistent, bioac</li> <li>vPvB: Very persistent</li> <li>VOC: Volatile Organic</li> <li>DNEL: Derived No-Eff</li> <li>PNEC: Predicted No-I</li> <li>LC50: Lethal concentr</li> <li>LD50: Lethal dose, 50</li> <li>UN: United Nations O</li> <li>ADR: European agree</li> <li>RID: Regulations como</li> <li>IMDG: International Mi</li> <li>IATA: International Air</li> </ul> | cumulable and toxic substances.<br>and very bioaccumulable substances<br>Compounds.<br>ect Level (REACH).<br>Effect Concentration (REACH).<br>ation, 50 percent.<br>percent.<br>"ganisation.<br>ment concerning the international ca<br>serning the international transport of o<br>aritime code for Dangerous Goods.<br>Transport Association. | nical Substances.<br>n Chemical Society).<br>omplex reaction products or biologica<br>s.<br>rriage of dangeous goods by road.   |  |  |
|                               | SAFETY DATA SHE   |   |   |  |  |
|                               | Safety Data Sheet in ad<br>HISTORIC:<br>Version: 1  | cordance with Article 31 of Regulatic<br><u>REVISION:</u><br>24/12/2021   | on (EC) No. 1907/2006 (REACH) and   | Annex of Reg   | julation (EU) No. 2020/878.  |
|                               | Version: 2<br>Version: 3  | 23/12/2022<br>11/03/2024  |   |  |  |
|                               |   | us Safety Data Sheet:<br>numerical, methodological and norm   | ative changes since the previous ver  | sion of the pre  | sent Safety Data Sheet are   |
| ditions<br>dling i<br>slation | mation of this Safety Data<br>sare beyond our knowled<br>instruction. It is always th   | a Sheet, is based on the present state<br>ge and control. The product is not to<br>e responsibility of the user to take all<br>Safety Data Sheet is meant as a desc<br>operties   | be used for other purposes than those necessary steps in order to fulfil the  | se specified, w<br>demand laid d   | ithout first obtaining written<br>lown in the local rules and  |